Adlai Nortye Pharmaceutical Co. Ltd. has described molecular glue degraders acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degraders reported to be useful for the treatment of cancer, viral infections, autoimmune disease and inflammatory disorders.